115 related articles for article (PubMed ID: 26293672)
1. Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.
Kluth M; Ahrary R; Hube-Magg C; Ahmed M; Volta H; Schwemin C; Steurer S; Wittmer C; Wilczak W; Burandt E; Krech T; Adam M; Michl U; Heinzer H; Salomon G; Graefen M; Koop C; Minner S; Simon R; Sauter G; Schlomm T
Oncotarget; 2015 Sep; 6(29):27966-79. PubMed ID: 26293672
[TBL] [Abstract][Full Text] [Related]
2. Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer.
Kluth M; Runte F; Barow P; Omari J; Abdelaziz ZM; Paustian L; Steurer S; Christina Tsourlakis M; Fisch M; Graefen M; Tennstedt P; Huland H; Michl U; Minner S; Sauter G; Simon R; Adam M; Schlomm T
Int J Cancer; 2015 Nov; 137(10):2354-63. PubMed ID: 26009879
[TBL] [Abstract][Full Text] [Related]
3. 13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer.
Kluth M; Scherzai S; Büschek F; Fraune C; Möller K; Höflmayer D; Minner S; Göbel C; Möller-Koop C; Hinsch A; Neubauer E; Tsourlakis MC; Sauter G; Heinzer H; Graefen M; Wilczak W; Luebke AM; Burandt E; Steurer S; Schlomm T; Simon R
Genes Chromosomes Cancer; 2018 Oct; 57(10):504-512. PubMed ID: 29923647
[TBL] [Abstract][Full Text] [Related]
4. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
5. Deletion of 8p is an independent prognostic parameter in prostate cancer.
Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R
Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
7. Deletion of 18q is a strong and independent prognostic feature in prostate cancer.
Kluth M; Graunke M; Möller-Koop C; Hube-Magg C; Minner S; Michl U; Graefen M; Huland H; Pompe R; Jacobsen F; Hinsch A; Wittmer C; Lebok P; Steurer S; Büscheck F; Clauditz T; Wilczak W; Sauter G; Schlomm T; Simon R
Oncotarget; 2016 Dec; 7(52):86339-86349. PubMed ID: 27861151
[TBL] [Abstract][Full Text] [Related]
8. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
El Gammal AT; Brüchmann M; Zustin J; Isbarn H; Hellwinkel OJ; Köllermann J; Sauter G; Simon R; Wilczak W; Schwarz J; Bokemeyer C; Brümmendorf TH; Izbicki JR; Yekebas E; Fisch M; Huland H; Graefen M; Schlomm T
Clin Cancer Res; 2010 Jan; 16(1):56-64. PubMed ID: 20028754
[TBL] [Abstract][Full Text] [Related]
10. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer.
Burdelski C; Reiswich V; Hube-Magg C; Kluth M; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wittmer C; Huland H; Simon R; Schlomm T; Sauter G; Steurer S
Clin Cancer Res; 2015 Aug; 21(15):3471-9. PubMed ID: 25925890
[TBL] [Abstract][Full Text] [Related]
12. CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.
Haferlach C; Bacher U; Kohlmann A; Schindela S; Alpermann T; Kern W; Schnittger S; Haferlach T
Haematologica; 2011 Jun; 96(6):829-36. PubMed ID: 21422114
[TBL] [Abstract][Full Text] [Related]
13. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T
Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445
[TBL] [Abstract][Full Text] [Related]
14. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.
Kluth M; Hesse J; Heinl A; Krohn A; Steurer S; Sirma H; Simon R; Mayer PS; Schumacher U; Grupp K; Izbicki JR; Pantel K; Dikomey E; Korbel JO; Plass C; Sauter G; Schlomm T; Minner S
Mod Pathol; 2013 Jul; 26(7):975-83. PubMed ID: 23370768
[TBL] [Abstract][Full Text] [Related]
15. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
Grupp K; Diebel F; Sirma H; Simon R; Breitmeyer K; Steurer S; Hube-Magg C; Prien K; Pham T; Weigand P; Michl U; Heinzer H; Kluth M; Minner S; Tsourlakis MC; Izbicki JR; Sauter G; Schlomm T; Wilczak W
Prostate; 2013 Nov; 73(15):1690-8. PubMed ID: 23843146
[TBL] [Abstract][Full Text] [Related]
16. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
[TBL] [Abstract][Full Text] [Related]
17. Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.
Burdelski C; Borcherding L; Kluth M; Hube-Magg C; Melling N; Simon R; Möller-Koop C; Weigand P; Minner S; Haese A; Michl HU; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Lebok P; Steurer S; Izbicki JR; Sauter G; Krech T; Büscheck F; Clauditz T; Schlomm T; Wilczak W
Oncotarget; 2017 May; 8(19):31494-31508. PubMed ID: 28415558
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer.
Marx A; Luebke AM; Clauditz TS; Steurer S; Fraune C; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Möller-Koop C; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Meiners J
Dis Markers; 2020; 2020():7050146. PubMed ID: 32377272
[TBL] [Abstract][Full Text] [Related]
19. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
[TBL] [Abstract][Full Text] [Related]
20. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]